TxCell (France), a clinical-stage biotechnology developing cell-based immunotherapies for chronic inflammatory and neurological diseases, closed a $15.9M Series C financing. Participants include CDC Entreprises, Auriga Partners and Seventure Partners.

Collective IP | The World’s Largest Technology Transfer Office Marketplace

Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets

Receive Collective IP Account Access HERE